ナノ粒子ドラッグデリバリー市場及びパイプラインインサイト...市場調査レポートについてご紹介

1. Introduction to Nanoparticle Technology for Drug Delivery

2. Nanoparticle Drug Delivery Mechanism
2.1 Protein Based Delivery Systems
2.2 Natural Polymers & Derivates
2.3 Polymeric Carriers
2.4 Dendrimers
2.5 Fullerene
2.6 Carbon Nanotubes

3. Application of Nanotechnology for Drug Delivery

4. Nanoparticle Drug Delivery Market Overview
4.1 Market Overview
4.2 Clinical Insight

5. Nanoparticle Drug Delivery Market Dynamics
5.1 Drivers
5.2 Challenges
5.3 Future Outlook

6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. Marketed Nanoparticle Drug

8. Suspended & Discontinued Nanoparticle Drug Profiles
8.1 No Development Reported
8.2 Discontinued
8.3 Suspended

9. Competitive Landscape
9.1 Abraxis BioScience
9.2 Access Pharmaceuticals
9.3 Alnylam Pharmaceuticals
9.4 Arrowhead Research
9.5 BIND Biosciences
9.6 iCeutica
9.7 NanoCarrier
9.8 Nippon Kayaku
9.9 Nanobiotix
9.10 Samyang

Figure 1-1: Nanoparticle Technology for Drug Delivery
Figure 1-2: Nanoparticle Class
Figure 2-1: Nanoparticle Drug Delivery System
Figure 4-1: Nanoparticle Drug Delivery Market (US$ Billion), 2013-2020
Figure 4-2: Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-3: Number Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-4: No Development in Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-5: Number of No Development in Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-6: Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-7: Number of Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-8: Suspended Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-9: Number of Suspended Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 9-1: Arrowhead Research Corporation Clinical Pipeline
Figure 9-2: NanoCarrier Clinical Pipeline